Clinical Trial

Cadonilimab Monotherapy as Neoadjuvant Therapy for Resectable II-IIIA Squamous Cell Lung Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 27, 2023 (before its estimated May 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Cadonilimab, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to retain the efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety profile of the combination therapy. The aim of this study is to evaluate the efficacy and safety of Cadonilimab monotherapy as neoadjuvant therapy for patients with resectable stage II-IIIA squamous cell lung cancer.
Trial Details
NCT Number NCT05784974
Lead Sponsor The First Hospital of Jilin University
Conditions Lung Cancer
Enrollment 37 participants
Start Date 2023-05-01
Primary Completion 2025-05-01 (estimated)
Study Completion 2028-05-01 (estimated)
Updated on ClinicalTrials.gov 2023-03-27